Clinical Trial: Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.

Study Status: Not yet recruiting
Recruit Status: Unknown status
Study Type: Interventional




Official Title: Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.

Brief Summary: The purpose of this study is to determine whether Levamisole plus prednisone can further improve the efficacy,extend the remission duration and reduce the dosage of prednisone for newly diagnosed warm antibody autoimmune hemolytic anemia.

Detailed Summary: The first line treatment in warm antibody autoimmune hemolytic anemia (WAIHA) is the glucocorticoid, but most of the patients, hemolytic events will frequently recurred after end of treatment or during the gradual reduction in dosage of prednisolone. As a result, many patients will finally accepted long-term glucocorticoids or other immunosuppressive drugs. How to reduce the relapse rate of AIHA is still difficult. Levamisole(LMS)is a immunoregulator.Recent studies have shown LMS has been widely used to treat autoimmune diseases ,such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. The purpose of this study is to determine whether LMS combined with prednisolone can further improve the efficacy,extend the remission duration and reduce the dosage of prednisone for newly diagnosed warm antibody autoimmune hemolytic anemia.
Sponsor: Institute of Hematology & Blood Diseases Hospital




Current Primary Outcome: Number of patients in each group in complete or partial remission [ Time Frame: one year ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Side effects [ Time Frame: 1year ]

Original Secondary Outcome: sustained response, cumulative doses of prednisone and side effects [ Time Frame: 1year ]

Information By: Institute of Hematology & Blood Diseases Hospital




Dates:
Date Received: April 13, 2012
Date Started: April 2012
Date Completion: April 2016
Last Updated: April 18, 2012
Last Verified: April 2012